Highlights:

• Third quarter order bookings of $18 million contribute to YTD 2012 orders of $64 million
• Backlog increases 34% in first nine months to a record $128 million at September 30, 2012
• Two VISIUS Surgical Theatres sold in third quarter to hospitals in the U.S. and China
• Appointment of Jay D. Miller as IMRIS President & COO strengthens operational leadership
• Oncology package for planned MR guided radiation therapy system receives FDA approval
• U.S. patent allowed for MR guided radiation therapy

http://www.imris.com/sites/default/files/pdf/Q3%202012%20Earnings%20Release%20Board.pdf